Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.

Soares IC, Simões K, de Souza JE, Okamoto OK, Wakamatsu A, Tuma M, Ritter G, Alves VA.

Appl Immunohistochem Mol Morphol. 2012 Mar;20(2):165-72.

PMID:
22553815
2.

Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.

Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, Bhaskaran N, Souchelnytskyi S, Hellman U, Filonenko V, Jungbluth AA, Odunsi K, Lloyd KO, Old LJ, Ritter G.

Cancer Immun. 2008 Feb 6;8:3.

3.

Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.

Kiyamova R, Shyian M, Lyzogubov VV, Usenko VS, Gout T, Filonenko V.

Exp Oncol. 2011 Sep;33(3):157-61.

PMID:
21956469
4.

The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.

Gryshkova V, Goncharuk I, Gurtovyy V, Khozhayenko Y, Nespryadko S, Vorobjova L, Usenko V, Gout I, Filonenko V, Kiyamova R.

Exp Oncol. 2009 Mar;31(1):37-42.

PMID:
19300415
5.

Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.

Lopes dos Santos M, Yeda FP, Tsuruta LR, Horta BB, Pimenta AA Jr, Degaki TL, Soares IC, Tuma MC, Okamoto OK, Alves VA, Old LJ, Ritter G, Moro AM.

PLoS One. 2013 Jul 31;8(7):e70332. doi: 10.1371/journal.pone.0070332. Print 2013.

6.

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB.

Mod Pathol. 2009 Mar;22(3):469-75. doi: 10.1038/modpathol.2008.206. Epub 2009 Jan 9.

7.

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2011 Aug;24(8):1146-55. doi: 10.1038/modpathol.2011.70. Epub 2011 Apr 8.

8.

Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.

Gryshkova V, Lituiev D, Savinska L, Ovcharenko G, Gout I, Filonenko V, Kiyamova R.

Hybridoma (Larchmt). 2011 Feb;30(1):37-42. doi: 10.1089/hyb.2010.0064.

PMID:
21466284
9.

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.

PMID:
21716157
10.

Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.

Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B.

Cancer. 2005 Apr 15;103(8):1631-43.

11.

Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas.

Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S.

Cancer. 1999 Feb 1;85(3):669-77.

PMID:
10091740
12.

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.

Lindegren S, Andrade LN, Bäck T, Machado CM, Horta BB, Buchpiguel C, Moro AM, Okamoto OK, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma MC, Chammas R, Hultborn R, Albertsson P.

PLoS One. 2015 May 13;10(5):e0126298. doi: 10.1371/journal.pone.0126298. eCollection 2015.

13.

Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.

Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8.

14.

Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.

Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC.

Hum Pathol. 2007 Jan;38(1):134-9. Epub 2006 Sep 25.

PMID:
16996567
15.

Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.

Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J.

Mod Pathol. 2006 Sep;19(9):1149-56. Epub 2006 May 26.

16.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549
17.

Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.

Kiyamova R, Gryshkova V, Ovcharenko G, Lituyev D, Malyuchik S, Usenko V, Khozhayenko Y, Gurtovyy V, Yin B, Ritter G, Old L, Filonenko V, Gout I.

Hybridoma (Larchmt). 2008 Aug;27(4):277-84. doi: 10.1089/hyb.2008.0015.

PMID:
18724815
18.

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.

Gynecol Oncol. 2006 Nov;103(2):405-16. Epub 2006 May 24.

PMID:
16725184
19.

Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray.

Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA.

Mod Pathol. 2005 Jan;18(1):119-26.

20.

The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.

Gynecol Oncol. 2006 Dec;103(3):831-40. Epub 2006 Aug 17.

PMID:
16919315
Items per page

Supplemental Content

Write to the Help Desk